Literature DB >> 34611764

Maternal embryonal leucine zipper kinase immunoreactivity in atypical teratoid/rhabdoid tumors: a study of 50 cases.

N Ravindra1, S Rao1, A Arivazhagan2, V Santosh3.   

Abstract

Atypical teratoid/rhabdoid tumors (AT/RTs) are aggressive embryonal neoplasms of the central nervous system that correspond to WHO grade IV and have a dismal prognosis. The latest Central Brain Tumor Registry of the United States data shows that AT/RT constitutes 16.6% of all embryonal tumors in children. The molecular hallmark of this tumor is pathogenic SMARCB1 genetic alterations resulting in the loss of INI-1 immunopositivity, with fewer tumors harboring SMARCA4 (BRG1) variants. Maternal embryonal leucine zipper kinase (MELK) is a member of the Snf1/AMPK family of serine/threonine-protein kinases involved in various processes such as cell cycle regulation, self-renewal of stem cells, apoptosis, and splicing regulation. Recent studies have highlighted the involvement of MELK in AT/RT and its possible therapeutic role. The purpose of this study was to review the histological and immunohistochemical profile of AT/RT with special reference to MELK  staining. In this retrospective study conducted over 6 years, all diagnosed cases of AT/RT, defined by loss of INI-1 immunopositivity, were retrieved and studied. Demographic details of patients and microscopic findings were analyzed, with special attention to histological patterns and immunohistochemistry profile including MELK immunoreactivity. There were 50 cases of AT/RT diagnosed in the specified period. Of the cases operated at our institute during this period, embryonal tumors constituted 20.6% of all pediatric brain tumors with AT/RT representing 12.6% of this subset. The median age at presentation was 3.5 years (range: 8 months-22 years) and there were three adult cases. Males outnumbered females by a ratio of 1.94:1. Tumor location was distributed equally between the supratentorial and infratentorial compartments. Characteristic rhabdoid cells were identified in 70% of cases. Areas with epithelial, mesenchymal, and undifferentiated tumor cells were seen in 8%, 20%, and 52% of cases, respectively. Cells with vacuolated cytoplasm were noted in 28% of cases. Immunohistochemistry (IHC) showed a polyimmunophenotypic profile with immunopositivity for GFAP in 70%, Vimentin in 100%, SMA in 68%, and EMA in 88% of cases, indicating the remarkable heterogeneity of the tumor cells. MELK immunopositivity was noted in 83.33% of cases. Thus, atypical teratoid/rhabdoid tumors are rare neoplasms. In line with other studies, we show that these tumors occur predominantly in very young children and display marked variability on histology and IHC with loss of INI-1. MELK is presumed to be an important molecule involved in cell cycle regulation, proliferation, and other critical functions. High expression of MELK in AT/RT may suggest its plausible role in neoplastic transformation of embryonic and postnatal multipotent neural progenitors which in turn could explain the diverse morphological and immunohistochemical characteristics observed in these tumors.
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  AT/RT; INI-1; Immunohistochemistry; Maternal embryonal leucine zipper kinase

Mesh:

Substances:

Year:  2021        PMID: 34611764     DOI: 10.1007/s00381-021-05335-0

Source DB:  PubMed          Journal:  Childs Nerv Syst        ISSN: 0256-7040            Impact factor:   1.475


  21 in total

1.  Case of atypical teratoid/rhabdoid tumor in an adult, with long survival.

Authors:  Kenta Takahashi; Hiroshi Nishihara; Masahito Katoh; Tomoaki Yoshinaga; Roshan Mahabir; Hiromi Kanno; Taichi Kimura; Mishie Tanino; Jun Ikeda; Yutaka Sawamura; Kazuo Nagashima; Shinya Tanaka
Journal:  Brain Tumor Pathol       Date:  2010-12-23       Impact factor: 3.298

2.  Atypical Teratoid/Rhabdoid Tumors Are Comprised of Three Epigenetic Subgroups with Distinct Enhancer Landscapes.

Authors:  Pascal D Johann; Serap Erkek; Marc Zapatka; Kornelius Kerl; Ivo Buchhalter; Volker Hovestadt; David T W Jones; Dominik Sturm; Carl Hermann; Maia Segura Wang; Andrey Korshunov; Marina Rhyzova; Susanne Gröbner; Sebastian Brabetz; Lukas Chavez; Susanne Bens; Stefan Gröschel; Fabian Kratochwil; Andrea Wittmann; Laura Sieber; Christina Geörg; Stefan Wolf; Katja Beck; Florian Oyen; David Capper; Peter van Sluis; Richard Volckmann; Jan Koster; Rogier Versteeg; Andreas von Deimling; Till Milde; Olaf Witt; Andreas E Kulozik; Martin Ebinger; Tarek Shalaby; Michael Grotzer; David Sumerauer; Josef Zamecnik; Jaume Mora; Nada Jabado; Michael D Taylor; Annie Huang; Eleonora Aronica; Anna Bertoni; Bernhard Radlwimmer; Torsten Pietsch; Ulrich Schüller; Reinhard Schneppenheim; Paul A Northcott; Jan O Korbel; Reiner Siebert; Michael C Frühwald; Peter Lichter; Roland Eils; Amar Gajjar; Martin Hasselblatt; Stefan M Pfister; Marcel Kool
Journal:  Cancer Cell       Date:  2016-02-25       Impact factor: 31.743

3.  Clinicopathologic prognostic factors in childhood atypical teratoid and rhabdoid tumor of the central nervous system: a multicenter study.

Authors:  Christelle Dufour; Annick Beaugrand; Marie Cécile Le Deley; Franck Bourdeaut; Nicolas André; Pierre Leblond; Anne-Isabelle Bertozzi; Didier Frappaz; Xavier Rialland; Fanny Fouyssac; Christine Edan; Jacques Grill; Marion Quidot; Pascale Varlet
Journal:  Cancer       Date:  2011-12-16       Impact factor: 6.860

4.  Atypical teratoid rhabdoid tumor of the central nervous system: Case series from a regional Tertiary Care Cancer Centre in South India.

Authors:  L Appaji; B S Aruna Kumari; K Govind Babu; C S Premalata; K P R Pramod; Gita R Bhat; Chinchu Prem
Journal:  J Cancer Res Ther       Date:  2017 Oct-Dec       Impact factor: 1.805

5.  Incidence of atypical teratoid/rhabdoid tumors in children: a population-based study by the Austrian Brain Tumor Registry, 1996-2006.

Authors:  Adelheid Woehrer; Irene Slavc; Thomas Waldhoer; Harald Heinzl; Nadine Zielonke; Thomas Czech; Martin Benesch; Johannes A Hainfellner; Christine Haberler
Journal:  Cancer       Date:  2010-08-24       Impact factor: 6.860

6.  Adult variant of atypical teratoid/rhabdoid tumor: immunohistochemical and ultrastructural confirmation of a rare tumor in the sella tursica.

Authors:  Facundo Las Heras; Kenneth P H Pritzker
Journal:  Pathol Res Pract       Date:  2010-08-11       Impact factor: 3.250

7.  Central nervous system atypical teratoid rhabdoid tumours: the Canadian Paediatric Brain Tumour Consortium experience.

Authors:  L Lafay-Cousin; C Hawkins; A S Carret; D Johnston; S Zelcer; B Wilson; N Jabado; K Scheinemann; D Eisenstat; C Fryer; A Fleming; C Mpofu; V Larouche; D Strother; E Bouffet; A Huang
Journal:  Eur J Cancer       Date:  2011-10-22       Impact factor: 9.162

8.  Atypical teratoid rhabdoid tumor (AT/RT) in adults: review of four cases.

Authors:  Addisalem T Makuria; Elisabeth J Rushing; Kevin M McGrail; Dan-Paul Hartmann; Norio Azumi; Metin Ozdemirli
Journal:  J Neurooncol       Date:  2008-03-28       Impact factor: 4.130

9.  MELK-a conserved kinase: functions, signaling, cancer, and controversy.

Authors:  Ranjit Ganguly; Ahmed Mohyeldin; Jordyn Thiel; Harley I Kornblum; Monique Beullens; Ichiro Nakano
Journal:  Clin Transl Med       Date:  2015-03-07

10.  Atypical teratoid/rhabdoid tumors (ATRTs) with SMARCA4 mutation are molecularly distinct from SMARCB1-deficient cases.

Authors:  Dörthe Holdhof; Pascal D Johann; Michael Spohn; Michael Bockmayr; Sepehr Safaei; Piyush Joshi; Julien Masliah-Planchon; Ben Ho; Mamy Andrianteranagna; Franck Bourdeaut; Annie Huang; Marcel Kool; Santhosh A Upadhyaya; Anne E Bendel; Daniela Indenbirken; William D Foulkes; Jonathan W Bush; David Creytens; Uwe Kordes; Michael C Frühwald; Martin Hasselblatt; Ulrich Schüller
Journal:  Acta Neuropathol       Date:  2020-12-17       Impact factor: 17.088

View more
  1 in total

1.  Commentary on: SMARCB1 as a novel diagnostic and prognostic biomarker for osteosarcoma.

Authors:  Consolato M Sergi
Journal:  Biosci Rep       Date:  2022-06-30       Impact factor: 3.976

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.